Technology ID
TAB-3756
PPTN as a Selective P2Y14 Receptor Antagonist for the Discovery of Treatments of Inflammatory Disorders
E-Numbers
E-129-2017-0
Lead Inventor
Jacobson, Kenneth (NIDDK)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NIDDK
ICs
NIDDK
This technology includes PPTN which can be used to study treatments of inflammatory diseases. PPTN is currently a useful pharmacological probe that many labs in the field of purinergic signaling are interested in obtaining. The availability of PPTN as a research tool will stimulate basic advances in the field and possibly eventually lead to new treatments. However, PPTN itself is unsuitable for therapeutic applications. Separately, we are working on new and improved antagonists of the P2Y14 receptor.
Commercial Applications
Useful for the study of future treatments for inflammatory disorders.
Competitive Advantages
This compound produced fully antagonizes the human P2Y14R with subnanomolar affinity with insignificant antagonism of other P2Y receptors at 10 µM, therefore it is highly selective.
Licensing Contact: